Download PDF

1. Company Snapshot

1.a. Company Description

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders.It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome.The company also engages in the developing of Axiomer RNA base-editing platform technology.


It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Show Full description

1.b. Last Insights on PRQR

ProQR Therapeutics N.V.'s recent performance was negatively impacted by its Q4 loss of $0.10 per share, exceeding the Zacks Consensus Estimate of a loss of $0.07. This earnings miss, coupled with a year-over-year increase in loss from $0.08 per share, suggests a slowdown in the company's financial performance. Additionally, the company's financial and operating results for the year ended December 31, 2024, showed a decline in revenue, further exacerbating the negative trend.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter

Apr -09

Source: defenseworld.net

Card image cap

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

Apr -08

Source: seekingalpha.com

Card image cap

ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event

Apr -08

Source: globenewswire.com

Card image cap

ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board

Apr -08

Source: globenewswire.com

Card image cap

ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026

Mar -25

Source: globenewswire.com

Card image cap

ProQR Therapeutics N.V. (PRQR) Presents at The Citizens Life Sciences Conference 2026 Transcript

Mar -18

Source: seekingalpha.com

Card image cap

ProQR (PRQR) Reports Q4 Loss, Lags Revenue Estimates

Mar -12

Source: zacks.com

Card image cap

ProQR Announces Year End 2025 Operating and Financial Results

Mar -12

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.43%)

6. Segments

RNA Based Therapeutics

Expected Growth: 11.43%

ProQR Therapeutics N.V.'s RNA-based therapeutics growth is driven by increasing adoption in rare genetic diseases, advancements in RNA editing technologies, and a strong pipeline of candidates. The company's focus on unmet medical needs, strategic partnerships, and expanding research collaborations also contribute to its 11.43% growth.

7. Detailed Products

Sepofarsen

An RNA-based oligonucleotide in development for the treatment of Leber Congenital Amaurosis 10 (LCA10), a severe inherited retinal disease.

QR-421a

An RNA-based oligonucleotide in development for the treatment of Usher syndrome type 2, a genetic disorder that causes hearing loss and vision loss.

QR-1123

An RNA-based oligonucleotide in development for the treatment of Autosomal Dominant Retinitis Pigmentosa (adRP), a genetic disorder that causes vision loss.

QR-313

An RNA-based oligonucleotide in development for the treatment of Fuchs Endothelial Corneal Dystrophy, a genetic disorder that causes vision loss.

8. ProQR Therapeutics N.V.'s Porter Forces

Forces Ranking

Threat Of Substitutes

ProQR Therapeutics N.V. is a biotech company that focuses on developing RNA-based therapies for severe genetic diseases. The threat of substitutes is medium because while there are other companies working on similar treatments, ProQR's RNA-based approach is unique and has shown promising results.

Bargaining Power Of Customers

ProQR Therapeutics N.V. is a biotech company that focuses on developing RNA-based therapies for severe genetic diseases. The bargaining power of customers is low because the company is still in the development stage and has not yet commercialized any products, giving customers limited bargaining power.

Bargaining Power Of Suppliers

ProQR Therapeutics N.V. relies on suppliers for raw materials and services necessary for its RNA-based therapies. The bargaining power of suppliers is medium because while there are some specialized suppliers, ProQR has some flexibility in choosing its suppliers.

Threat Of New Entrants

The biotech industry is highly competitive, and new entrants can easily disrupt the market. The threat of new entrants is high because ProQR Therapeutics N.V. operates in a highly competitive market with many established players and new entrants.

Intensity Of Rivalry

The biotech industry is highly competitive, and ProQR Therapeutics N.V. operates in a crowded market with many established players. The intensity of rivalry is high because companies are constantly competing for funding, talent, and market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 12.49%
Debt Cost 5.42%
Equity Weight 87.51%
Equity Cost 5.42%
WACC 5.42%
Leverage 14.27%

11. Quality Control: ProQR Therapeutics N.V. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
NewAmsterdam Pharma

A-Score: 4.2/10

Value: 6.2

Growth: 4.0

Quality: 4.5

Yield: 0.0

Momentum: 10.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Atai Life Sciences

A-Score: 3.9/10

Value: 6.2

Growth: 2.9

Quality: 4.9

Yield: 0.0

Momentum: 9.5

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
LAVA Therapeutics

A-Score: 3.5/10

Value: 6.8

Growth: 5.4

Quality: 2.6

Yield: 0.0

Momentum: 5.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Pharma Mar

A-Score: 3.4/10

Value: 0.9

Growth: 4.4

Quality: 8.1

Yield: 1.2

Momentum: 3.0

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Calliditas Therapeutics

A-Score: 3.0/10

Value: 6.0

Growth: 4.2

Quality: 3.8

Yield: 0.0

Momentum: 4.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
ProQR Therapeutics

A-Score: 2.9/10

Value: 6.6

Growth: 6.6

Quality: 4.1

Yield: 0.0

Momentum: 0.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

1.99$

Current Price

1.99$

Potential

-0.00%

Expected Cash-Flows